---

---

symbols : Azn   

save search

---

Global Type 2 Diabetes Treatment Market Outlook Report 2022-2023 & 2027: Patent Cliff, Oral Antidiabetics, and Growing Focus on Accessibility and Affordability of Medicine Bolsters Growth
Published: 2023-01-04 (Crawled : 23:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| 1.64% | O: -0.93% H: 3.08% C: 3.08%
NVO | News | $126.16 -1.93% -0.23% 3.1M |

Health Technology

| -5.94% | O: -0.89% H: 1.18% C: 0.52%
NVS | News | $98.35 1.1% 0.0% 2.2M |

Health Technology

| 7.64% | O: -0.85% H: 0.2% C: -0.29%
JNJ | News | $148.53 -0.69% -0.14% 9.6M |

Health Technology

| -16.92% | O: -0.62% H: 0.54% C: -0.12%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -4.45% | O: -3.07% H: 0.0% C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 1.94% | O: -0.49% H: 1.65% C: 0.94%
treatment patent global report growing diabetes growth market

---

Global Bronchitis Treatments (Acute, Chronic) Market Report 2022-2027 Featuring Leading Players - AstraZeneca, Bayer, Cipla, Sanofi and Pfizer
Published: 2022-12-30 (Crawled : 15:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K |

Health Technology

| 13.01% | O: 1.13% H: 0.0% C: 0.0%
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| -2.08% | O: 0.77% H: 0.0% C: -0.74%
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| 3.84% | O: 1.08% H: 0.0% C: -0.25%
NVS | News | $98.35 1.1% 0.0% 2.2M |

Health Technology

| 7.93% | O: -0.01% H: 0.08% C: -0.95%
GSK | News | $40.86 -0.92% -0.15% 1.7M |

Health Technology

| 17.39% | O: -0.37% H: 0.89% C: 0.4%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -3.07% | O: -0.39% H: 0.0% C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 4.04% | O: -0.46% H: 0.38% C: 0.01%
global report sanofi market

---

Global Precision Cancer Therapeutics Market Report 2022: Overview of Disease Epidemiology, Leading Product sales, Market Estimates and Forecasts, and Competitive Summary of Leading Providers
Published: 2022-12-30 (Crawled : 15:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| -2.08% | O: 0.77% H: 0.0% C: -0.74%
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| 3.84% | O: 1.08% H: 0.0% C: -0.25%
PFE | News 4 | $26.27 -0.19% -0.15% 23M |

Health Technology

| -48.72% | O: -0.08% H: 0.21% C: -0.1%
NVS | News | $98.35 1.1% 0.0% 2.2M |

Health Technology

| 7.93% | O: -0.01% H: 0.08% C: -0.95%
JNJ | News | $148.53 -0.69% -0.14% 9.6M |

Health Technology

| -15.71% | O: -0.04% H: 0.16% C: -0.47%
BMY | $48.86 -0.27% -0.02% 16M |

Health Technology

| -32.05% | O: 0.04% H: 0.21% C: -0.25%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -3.07% | O: -0.39% H: 0.0% C: 0.0%
GILD | $67.07 0.06% 0.06% 8.3M |

Health Technology

| -21.38% | O: 0.08% H: 0.66% C: 0.61%
EXEL | $23.7 1.76% 1.73% 1.5M |

Health Technology

| 48.72% | O: -0.32% H: 2.91% C: 2.75%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 4.04% | O: -0.46% H: 0.38% C: 0.01%
global disease report therapeutics cancer market

---

Extensive Stage Small Cell Lung Cancer Global Market Report 2022: Need of Potential Treatments to Improve Quality of Life Drives Sector
Published: 2022-12-22 (Crawled : 17:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| 4.2% | O: -0.17% H: 0.0% C: 0.0%
JAZZ | $108.38 -1.18% -1.19% 400K |

Health Technology

| -30.79% | O: -0.06% H: 1.27% C: 0.93%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 4.34% | O: -0.04% H: 0.32% C: 0.31%
lung global report life potential cancer market

---

Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors
Published: 2022-12-19 (Crawled : 13:20) - globenewswire.com
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| 3.85% | O: 0.99% H: 0.06% C: 0.06%
VERU | $1.325 3.92% 3.77% 1.5M |

Health Technology

| -74.55% | O: 0.4% H: 0.4% C: -3.99%
FBIO | $1.785 -1.38% -1.4% 120K |

Health Technology

| 212.07% | O: 3.79% H: 3.82% C: -8.21%
ATXI | $0.0949 -29.18% -41.2% 12M |

Health Technology

| -89.52% | O: -0.81% H: 1.63% C: -6.5%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 4.28% | O: -0.07% H: 0.01% C: -0.62%
biotech

---

Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology
Published: 2022-12-16 (Crawled : 13:00) - biospace.com/
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| 1.68% | O: -1.84% H: 0.05% C: -0.25%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 1.59% | O: -2.55% H: 0.44% C: -0.03%
cancer

---

The Worldwide mRNA Therapeutics Industry is Expected to Reach $37.7 billion by 2030
Published: 2022-12-15 (Crawled : 17:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| 0.39% | O: 0.14% H: 0.4% C: -1.41%
SGMO | News | $0.4911 -5.72% -6.07% 1.2M |

Health Technology

| -84.93% | O: -1.16% H: 1.17% C: -3.23%
MRNA | News S | $108.82 0.86% 0.85% 3.4M |

Health Technology

| -48.37% | O: -0.64% H: 2.33% C: -0.17%
CVAC | $2.51 -3.46% -3.59% 1.1M |

Health Technology

| -63.74% | O: -1.39% H: 1.41% C: -4.24%
CRSP | News 4 | $55.66 -1.33% -1.35% 910K |

Health Technology

| 12.39% | O: -2.23% H: 2.67% C: -3.2%
BNTX | News | $88.18 -0.35% -0.35% 280K |

Health Technology

| -52.44% | O: 0.13% H: 1.45% C: -2.28%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 0.58% | O: -0.58% H: 0.11% C: -0.41%
expected mrna therapeutics

---

Peripheral neuropathy treatment market size to increase by USD 372.56 million: North America to contribute 33% of market growth - Technavio
Published: 2022-12-15 (Crawled : 03:00) - prnewswire.com
ENDPQ | News | $0.0007 -50.0% 1K |

n/a

| -95.15% | O: -3.03% H: 3.38% C: -7.75%
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| 0.39% | O: 0.14% H: 0.4% C: -1.41%
VTRS | News A | $11.55 1.67% 1.65% 7.2M |

Health Technology

| 0.35% | O: -0.53% H: 0.71% C: -1.07%
NVS | News | $98.35 1.1% 0.0% 2.2M |

Health Technology

| 6.84% | O: -0.71% H: 0.08% C: -1.07%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 0.58% | O: -0.58% H: 0.11% C: -0.41%
america treatment growth market

---

Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer
Published: 2022-12-14 (Crawled : 19:00) - biospace.com/
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| 0.57% | O: -1.61% H: 1.82% C: 1.82%
GNPX | $2.31 6.77% 20K |

Health Technology

| 102.05% | O: 2.34% H: 5.98% C: -0.85%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 1.83% | O: 0.76% H: 1.04% C: 0.47%
reqorsa lung trial approval review cancer

---

Datopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in Patients with Metastatic Triple Negative Breast Cancer in Two Early Trials
Published: 2022-12-09 (Crawled : 17:00) - biospace.com/
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 2.43% | O: 0.8% H: 0.4% C: -0.24%
trials breast cancer negative

---

Lung cancer therapeutics market size to grow by USD 10,204.33 million: High prevalence of lung cancer remains key growth driver - Technavio
Published: 2022-12-08 (Crawled : 08:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K |

Health Technology

| 10.33% | O: 1.92% H: 0.0% C: 0.0%
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| -0.19% | O: 0.5% H: 0.16% C: 0.16%
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| 3.16% | O: 2.24% H: 0.0% C: 0.0%
NVSEF | News | $96.0 6.88% 52K |

Health Technology

| 26.59% | O: 0.0% H: 0.0% C: 0.0%
ALPMY | News | $9.49 -1.11% 480K |

Manufacturing

| -38.14% | O: 1.24% H: 0.97% C: 0.19%
NVS | News | $98.35 1.1% 0.0% 2.2M |

Health Technology

| 7.77% | O: -1.17% H: 1.09% C: 1.01%
GSK | News | $40.86 -0.92% -0.15% 1.7M |

Health Technology

| 11.82% | O: -1.41% H: 1.75% C: 0.66%
ABBV | News | $167.8 -1.03% -0.06% 4.1M |

Health Technology

| 2.5% | O: 0.0% H: 0.5% C: 0.36%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -0.83% | O: -1.32% H: 0.0% C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 2.9% | O: 0.13% H: 0.76% C: 0.33%
AMGN | News | $273.085 -0.17% -0.17% 2.5M |

Health Technology

| -4.28% | O: 0.26% H: 0.03% C: -0.33%
lung therapeutics cancer growth market

---

Non-steroidal Anti-inflammatory Drugs Market Research Report by Disease Indication, Drugs, Route of Administration, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-12-07 (Crawled : 16:00) - prnewswire.com
RBGPF | News | $52.06 6.46% 4.8K |

Consumer Non-Durables

| -26.38% | O: 0.06% H: 3.15% C: 0.15%
GLAXF | News | $19.54 -14.18% 2.6K |

Health Technology

| 3.66% | O: 0.74% H: 0.0% C: -6.74%
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| -2.92% | O: 1.62% H: 0.0% C: -4.28%
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| 2.6% | O: -0.56% H: 0.61% C: 0.01%
RBGLY | News | $10.59 -2.05% 850K |

Manufacturing

| -26.16% | O: 0.51% H: 0.48% C: -0.14%
VTRS | News A | $11.55 1.67% 1.65% 7.2M |

Health Technology

| 3.93% | O: 0.0% H: 0.55% C: -0.27%
ZTS | $150.88 0.88% -0.5% 3.6M |

Health Technology

| -2.28% | O: -0.06% H: 0.54% C: -1.77%
PRGO | $31.23 2.43% 0.0% 960K |

Health Technology

| -3.91% | O: -0.09% H: 0.47% C: -0.28%
GSK | News | $40.86 -0.92% -0.15% 1.7M |

Health Technology

| 8.76% | O: -0.98% H: 0.24% C: -1.78%
LLY | News | $732.2 -1.81% 0.18% 2.1M |

Health Technology

| 100.53% | O: 0.21% H: 1.6% C: 0.72%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| 4.3% | O: 5.18% H: 0.0% C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 3.34% | O: 0.45% H: 0.64% C: -0.03%
covid-19 research global disease report impact distribution market

---

ENHERTU® Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast03
Published: 2022-12-07 (Crawled : 15:00) - biospace.com/
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 3.34% | O: 0.45% H: 0.64% C: -0.03%
enhertu risk breast positive cancer her2- her2 metastatic breast cancer

---

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Achieved Statistically Significant Overall Survival, Reducing the Risk of Death by 36% Vs. Trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Breast cancer in DESTINY-Breast03
Published: 2022-12-07 (Crawled : 14:00) - biospace.com/
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 3.34% | O: 0.45% H: 0.64% C: -0.03%
enhertu risk breast cancer her2- her2 metastatic breast cancer

---

Travel Vaccine Global Market Report 2022: Growth Potential in Emerging Economies Presents Lucrative Opportunities
Published: 2022-12-06 (Crawled : 18:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| 6.08% | O: 0.74% H: 8.46% C: 8.46%
JNJ | News | $148.53 -0.69% -0.14% 9.6M |

Health Technology

| -16.29% | O: 0.64% H: 0.04% C: -2.12%
ABT | News | $106.89 -0.65% -0.22% 5.1M |

Health Technology

| 2.07% | O: -0.4% H: 0.4% C: -1.08%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| 4.65% | O: 0.33% H: 0.0% C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 3.55% | O: -0.48% H: 1.59% C: 0.69%
global report vaccine travel potential growth market

---

Medikine Appoints Roland Buelow, Ph.D., to Board of Directors
Published: 2022-12-06 (Crawled : 17:00) - biospace.com/
GNMSF | News | $290.34 3.83% 340 |

Health Technology

| -36.34% | O: -0.15% H: 1.16% C: -0.9%
JNJ | News | $148.53 -0.69% -0.14% 9.6M |

Health Technology

| -16.29% | O: 0.64% H: 0.04% C: -2.12%
ABBV | News | $167.8 -1.03% -0.06% 4.1M |

Health Technology

| 3.42% | O: 0.05% H: 0.22% C: -0.19%
SGEN | $228.74 0.1% 20M |

Health Technology

| 88.7% | O: -0.49% H: 0.12% C: -2.25%
LGND | $70.87 1.4% 1.38% 150K |

Health Technology

| 0.27% | O: 0.3% H: 0.0% C: -2.98%
GMAB | News | $28.47 -0.32% -0.32% 460K |

Health Technology

| -37.97% | O: 0.11% H: 0.02% C: -1.74%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 3.55% | O: -0.48% H: 1.59% C: 0.69%
AMGN | News | $273.085 -0.17% -0.17% 2.5M |

Health Technology

| -3.99% | O: 0.33% H: 0.56% C: -0.89%

---

Fortress Biotech to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference
Published: 2022-12-06 (Crawled : 15:00) - biospace.com/
FBIO | $1.785 -1.38% -1.4% 120K |

Health Technology

| 156.99% | O: -2.03% H: 2.9% C: -3.67%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 3.55% | O: -0.48% H: 1.59% C: 0.69%
conference biotech medical aesthetic

---

Biosimilar Therapeutic Peptides Global Market to Reach $3.5 Billion by 2026 at a CAGR of 30.3%
Published: 2022-12-06 (Crawled : 12:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| 6.08% | O: 0.74% H: 8.46% C: 8.46%
NVSEF | News | $96.0 6.88% 52K |

Health Technology

| 27.69% | O: -1.97% H: 0.05% C: 0.05%
NVO | News | $126.16 -1.93% -0.23% 3.1M |

Health Technology

| 1.23% | O: -0.85% H: 0.46% C: -0.17%
NVS | News | $98.35 1.1% 0.0% 2.2M |

Health Technology

| 8.69% | O: 0.03% H: 0.26% C: -0.27%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| 4.65% | O: 0.33% H: 0.0% C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 3.55% | O: -0.48% H: 1.59% C: 0.69%
AMGN | News | $273.085 -0.17% -0.17% 2.5M |

Health Technology

| -3.99% | O: 0.33% H: 0.56% C: -0.89%
global biosimilar market

---

Type 2 diabetes market 2023-2027: 5-year (2017-2021) historic industry size and analysis of 15 vendors and 7 countries - Technavio
Published: 2022-12-06 (Crawled : 04:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K |

Health Technology

| 13.94% | O: 2.04% H: 8.0% C: 7.71%
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| 6.08% | O: 0.74% H: 8.46% C: 8.46%
NVSEF | News | $96.0 6.88% 52K |

Health Technology

| 27.69% | O: -1.97% H: 0.05% C: 0.05%
NVS | News | $98.35 1.1% 0.0% 2.2M |

Health Technology

| 8.69% | O: 0.03% H: 0.26% C: -0.27%
GSK | News | $40.86 -0.92% -0.15% 1.7M |

Health Technology

| 17.29% | O: -1.19% H: 14.39% C: 9.15%
BAX | $40.93 -0.22% 0.0% 2.2M |

Health Technology

| -20.04% | O: -0.58% H: 1.71% C: 1.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| 4.65% | O: 0.33% H: 0.0% C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 3.55% | O: -0.48% H: 1.59% C: 0.69%
AMGN | News | $273.085 -0.17% -0.17% 2.5M |

Health Technology

| -3.99% | O: 0.33% H: 0.56% C: -0.89%
diabetes market

---

Cancer Gene Therapy Market To Reach a Valuation of USD 4047.8 Million by 2028 - Comprehensive Research Report by BrandEssence Market Research
Published: 2022-12-02 (Crawled : 12:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K |

Health Technology

| 10.08% | O: 1.41% H: 0.0% C: -3.13%
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| 1.48% | O: -0.61% H: 0.08% C: -0.29%
NVS | News | $98.35 1.1% 0.0% 2.2M |

Health Technology

| 10.06% | O: -1.08% H: 1.44% C: 1.28%
GSK | News | $40.86 -0.92% -0.15% 1.7M |

Health Technology

| 17.73% | O: -0.29% H: 1.55% C: 1.2%
CRNX G | $43.32 -2.04% -2.08% 420K |

Health Technology

| 151.68% | O: -0.57% H: 5.9% C: 5.44%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 3.67% | O: -0.23% H: 0.79% C: 0.43%
ADAP | $1.085 -4.83% -5.07% 780K |

Health Technology

| -43.56% | O: -0.99% H: 6.5% C: 3.0%
research report therapy cancer market

---

Gainers vs Losers

62%

38%

Top 10 Gainers

CSSE 4 | $0.4323 183.85% 64.77% 220M |

Consumer Services

BOF | $1.99 70.09% 41.21% 110M |

ILAG | $0.51 6.03% 40.62% 1.7M |

LICN | $0.941 68.04% 40.49% 15M |

AMST | $3.31 65.5% 39.58% 70M |

Technology Services

MTC | $3.615 61.38% 38.04% 9.3M |

Technology Services

WIMI | $1.15 58.53% 36.92% 19M |

Technology Services

AIH | $0.45 12.5% 30.92% 320K |

Health Services

MULN | News | $3.78 38.46% 27.78% 13M |

Information

RILY | $29.86 37.48% 27.26% 12M |

Finance

---

Your saved searches

---